Clinical Trials Browser

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

NCT05560009 2025-07-10

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Completed

9 enrolled

Sarcoma

NCT04213794 2025-02-20

TOASTIT

Phase EARLY_PHASE1 Terminated

2 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

NCT03240861 2023-11-01

NYESO SCT

Phase 1 Terminated

5 enrolled

Sarcoma

NCT01462630 2022-08-19

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase 2 Completed

29 enrolled 10 charts

Sarcoma

Hemangiosarcoma, Sarcoma

NCT03613259 2020-06-09

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

Phase EARLY_PHASE1 Withdrawn

Sarcoma

NCT00123773 2016-02-26

Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

Phase 2 Completed

1,075 enrolled

GenitourinaryGynecologicPlasma cellSarcoma

Kidney Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Sarcoma, Testicular Neoplasms

NCT00123786 2016-02-25

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma

Phase 2 Terminated

4 enrolled

Sarcoma

NCT02309242 2015-08-21

Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study

Phase NA Unknown

60 enrolled

Sarcoma

Sarcoma, Osteosarcoma

Clinical Trials

68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas

Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

TOASTIT

NYESO SCT

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma

Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study